Mirum Pharmaceuticals Inc at UBS BioPharma Conference Transcript
All right. I think we're going to get started. We're running a minute or 2 behind. I'm Ellie Merle, one of the biotech analysts here at UBS. Very happy to have Mirum Pharma here with us at the UBS Biopharma Conference in Miami.
Joining us from Mirum is Eric Bjerkholt, Chief Financial Officer; and Andrew McKibben, VP, Investor Relations and Finance. Guys, thanks so much for joining us. Maybe just to kick it off, you guys have a pretty wide portfolio in most commercial and clinical programs. Can you give us an overview of your pipeline and what you see as the key milestones over the next year?
Absolutely. And Ellie, thanks for having us. It's really fun to be here. And before I start answering the questions, let me say, both Andrew and I will be making forward-looking statements. So please refer to our SEC filings.
So we are building a leading company in rare diseases. Currently, we have 3 approved products for liver
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
